The company
CytomX Therapeutics, Inc.
CTMX · Nasdaq
CTMX stood above a rising 150-day average in 27 of the last 52 weekly readings, and has been out of that trend for the last 25 weeks. It is 36.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 25
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $3.4M
- Officials’ trades on record
- 1
- Institutions holding
- 176 (+1)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 27 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
1 disclosed lines: House 0, Senate 0, executive 1; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Eric S. Lander Executive branch: Office of Government EthicsOffice of Science and Technology Policy | sold | $15k–$50k | 10 Jun 2021filed 8 Sep 2021 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Christopher OgdenChief Financial Officer | sold | 1,624at $3.05 | 15 Jun 2026filed 17 Jun 2026 |
| Christopher OgdenChief Financial Officer | sold | 19,323at $6.42 | 17 Mar 2026filed 19 Mar 2026 |
| Marcia BelvinSVP, Chief Scientific Officer | sold | 31,492at $6.42 | 17 Mar 2026filed 19 Mar 2026 |
| Sean A. McCarthyCEO | sold | 118,969at $6.42 | 17 Mar 2026filed 19 Mar 2026 |
| Yu-Waye ChuChief Medical Officer | sold | 21,279at $6.42 | 17 Mar 2026filed 19 Mar 2026 |
| Sean A. McCarthyCEO | sold | 101,793at $4.54 | 6 Nov 2025filed 16 Oct 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 32,714,937$122.7M | +759,300+2.4% |
| Kynam Capital Management, LPadded · filed 14 Aug 2026 | 21,703,093$81.4M | +6,690,000+44.6% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 17,559,822$65.8M | +12,331,542+235.9% |
| BANK OF AMERICA CORPadded · filed 14 Aug 2026 | 15,082,617$56.6M | +4,879,832+47.8% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 11,747,236$44.1M | +6,083,828+107.4% |
| PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026 | 10,439,185$39.1M | +340,361+3.4% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 8,525,457$32.0M | -207,661−2.4% |
| Point72 Asset Management, L.P.reduced · filed 14 Aug 2026 | 7,811,033$29.3M | -64,357−0.8% |
| WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026 | 5,168,961$19.4M | +1,585,976+44.3% |
| Venrock Adviser, LLCreduced · filed 14 Aug 2026 | 4,982,124$18.7M | -5,000,000−50.1% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.